Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2022

View Archived Issues

MAO mutant zebrafish exhibit abnormal brain development

ATR kinase blockade useful for treating pancreatic ductal adenocarcinoma

Idorsia Pharmaceuticals discovers Kv7 potassium channel activators

Charite-Universitaetsmedizin Berlin, Sapreme Technologies present new saponin derivatives

New kappa-opioid receptor agonists identified at Humanwell Pharmaceutical US

Ortho-hIL-2/ortho-hIL-2Rbeta pair enhances antitumor efficacy of engineered T cells

Yes targeting useful for treatment of HCC, researchers suggest

Sodium salt of a quinoline derivative shows anticancer efficacy in vivo

Once-daily dermal administration of Epoladerm well tolerated in four preclinical studies

Eisbach Bio and MD Anderson partner to target synthetic lethality in cancer

ProMIS initiates program to develop monoclonal antibodies to treat schizophrenia

BetterLife reports data from in vivo oral bioavailability and food-effect PK study with BETR-001

Evotec and Lilly collaborate on drug discovery for metabolic diseases

Almirall and IRB Barcelona collaborate on molecular glue degraders for skin diseases

NT-I7 promotes longer survival in murine models of glioma through CD8+ T cells

Subcutaneous nanocarrier-mediated delivery of rapamycin

Amyloid aggregates differ in familial and sporadic AD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...